TITLE

ThromboGenics Stock Up on Microplasmin Data

PUB. DATE
April 2010
SOURCE
Bioworld Week;4/26/2010, Vol. 18 Issue 17, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that ThromboGenics NV's traded shares have reached an all-time high during its early trading on April 20, 2010 in view of the success of the Phase III trials of its lead drug microplasmin for the treatment of symptomatic focal vitreomacular adhesion (VMA).
ACCESSION #
49802497

 

Related Articles

  • Clinic Roundup.  // BioWorld Today;8/23/2011, Vol. 22 Issue 163, p5 

    This section offers news briefs on drug clinical trials, which include the adult mesenchymal precursor cell product of Mesoblast Ltd. and the ocriplasmin trial for focal vitreomacular adhesion developed by ThromboGenics NV.

  • ThromboGenics Stock Climbs on Microplasmin Phase III Data. Sheridan, Cormac // BioWorld Today;4/21/2010, Vol. 21 Issue 76, p1 

    The article reports that shares in ThromboGenics NV reached its highest price at 18.80 euros following news that its lead drug candidate microplasmin posted good results in the first of two Phase III trials for treating symptomatic focal vitreomacular adhesion (VMA). The trial, which involved...

  • Financings Roundup.  // BioWorld Today;9/21/2007, Vol. 18 Issue 184, p6 

    The article reports that ThromboGenics NV strengthened its cash position by &euro5.1 million through the exercise of 1.1 million pledges. It is stated that the company's number of outstanding shares increased to 25.5 million. ThromboGenics has various programs in the clinic which is in Phase II...

  • THROMBOGENICS STARTS PHASE IIA OF MICROPLASMIN FOR STROKE.  // Worldwide Biotech;Nov2006, Vol. 18 Issue 11, p3 

    The article reports on a phase IIa trial initiated by ThromboGenics NV to evaluate microplasmin for the intra-arterial treatment of stroke. The study will enroll patients with acute vertebro-basilar artery occlusion. The purpose is to obtain initial safety information in the acute stroke patient...

  • THROMBOGENICS SIGNS DEAL WITH MSD FOR MICROPLASIN SUPPLY.  // Worldwide Biotech;Nov2010, Vol. 22 Issue 11, p4 

    This article focuses on the supply agreement signed between ThromboGenics NV and MSD Biologics (UK) Ltd. for the production of microplasmin. The deal is expected by ThromboGenics to address its long-term commercial needs for bulk drug substance of this therapeutic agent. Particular focus is...

  • ThromboGenics Stock Sky High on Microplasmin Phase III Data. Sheridan, Cormac // BioWorld International;4/21/2010, Vol. 15 Issue 16, p1 

    The article reports on the stock gains posted by ThromboGenics NV in April 2010 following disclosure that its lead drug candidate, microplasmin, reached the primary endpoint in the first of two Phase III trials in the treatment of symptomatic focal vitreomacular adhesion (VMA). A brief...

  • Thrombogenics' Clot-Busting Drug Moves into Phase III. Nuala, Moran // BioWorld International;2/9/2011, Vol. 16 Issue 6, p2 

    The article focuses on the Phase III trial for the THR-100 staphylokinase clot-busting drug of Thrombogenics NV. It is expected to be completed in 2011, leading to a launch that could coincide with the approval of microplasmin for the treatment of symptomatic focal vitreomacular adhesion. The...

  • CLINIC ROUNDUP.  // BioWorld Today;5/7/2010, Vol. 21 Issue 88, p10 

    This section presents an update on clinical trials. BioInvent International AB and ThromboGenics NV released positive results from their Phase II trial of the TB-402 long-acting anticoagulant. Oramed Pharmaceuticals Inc. reported the results of its Phase IIb trial of ORMD-0801 oral insulin...

  • BioInvent Tumbles on Double Blow to ThromboGenics Deal. Sheridan, Cormac // BioWorld Today;6/6/2012, Vol. 23 Issue 109, p1 

    The article reports on the implication of the move of BioInvent International AB and ThromboGenics NV to halt development of an anticoagulation antibody TB-402 following unfavorable data from a Phase IIb trial against Xarelto. Roche Holding AG also decided to exit a three-way alliance to develop...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics